CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,083,813 | -38.7% | 324,499 | -10.8% | 0.00% | -50.0% |
| Q2 2023 | $11,562,150 | +25.7% | 363,704 | -3.5% | 0.00% | 0.0% |
| Q1 2023 | $9,196,421 | -5.0% | 377,057 | +22.8% | 0.00% | 0.0% |
| Q4 2022 | $9,681,203 | +39.4% | 306,950 | +24.9% | 0.00% | 0.0% |
| Q3 2022 | $6,946,000 | +159.9% | 245,797 | +143.1% | 0.00% | +100.0% |
| Q2 2022 | $2,673,000 | -7.2% | 101,104 | +22.9% | 0.00% | 0.0% |
| Q1 2022 | $2,880,000 | -78.9% | 82,265 | -80.5% | 0.00% | -66.7% |
| Q4 2021 | $13,671,000 | -9.1% | 421,688 | -17.3% | 0.00% | 0.0% |
| Q3 2021 | $15,038,000 | +475.7% | 509,747 | +167.9% | 0.00% | +200.0% |
| Q1 2021 | $2,612,000 | +456.9% | 190,266 | +572.1% | 0.00% | – |
| Q4 2020 | $469,000 | – | 28,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |